This podcast episode explores non-hallucinogenic serotonin agonists, a promising new direction in psychedelic research. The discussion focuses on compounds that can potentially deliver therapeutic benefits of psychedelics without causing hallucinations, with particular attention to Psilera's PSIL-006 compound.

The conversation covers key topics including:

- How these compounds work through partial activation of the 5HT2A receptor

- Pre-clinical studies showing anxiety reduction without psychedelic effects

- Potential applications in treating depression, PTSD, and other disorders

- Current challenges in research and development

- The broader implications for mental healthcare

The episode features an in-depth discussion of both the molecular mechanisms and broader implications for mental health treatment, while exploring the question of whether the subjective psychedelic experience is necessary for therapeutic benefits.